Chapter 304 - 218: The Hongmen Banquet and the Drop: The "Fengmu Tiada" Entry

Chapter 304: Chapter 218: The Hongmen Banquet and the Drop: The "Fengmu Tiada" Entry

Xu Kunlin was still hesitant.

"President Xie, I think this plan is too risky."

"While it’s true that our new drug, Sorafenib, has shown significant efficacy in treating late-stage liver cancer, we still saw a lot of toxic side effects during the preliminary verification stage."

"So far, my research has cataloged the following: circulatory system side effects like increased blood pressure, subungual linear hemorrhages, cerebrovascular accidents, and thrombotic diseases; adverse skin reactions like hand-foot syndrome and facial erythema; diarrhea; adverse reactions in the hematopoietic system; and so on. There’s also a chance it could lead to hepatobiliary system abnormalities and increase the risk of bleeding..."

"While some side effects can be mitigated or eliminated through dosage control and corresponding symptomatic treatments, we still can’t completely avoid severe adverse reactions..."

"If we get certification by faking the data and the drug actually goes to market, we won’t be able to bear the responsibility if a patient dies from a severe adverse reaction."

Xu Kunlin shook his head in refusal.

Xie Bin coaxed him patiently:

"But, the probability of this severe adverse reaction is very low, right?"

"And if we recall it quickly, no agency will have time to discover the mechanism behind its toxic side effects, right?"

"The new drug itself is aimed at late-stage liver cancer patients. Even without side effects, the five-year survival rate is very low, right?"

"Besides, our new drug does, to some extent, significantly improve the patients’ conditions, doesn’t it?"

"So, think about it. We launch a new drug that has passed FDA and IRB certification. It has proven efficacy, but also some unknown side effects and a low probability of severe adverse reactions. Then, we proactively recall it after a short time. Wouldn’t that better reflect Pfizer’s sense of responsibility, professionalism, and rigor?"

"Here in Jin Country, for a company like Pfizer, an FDA certification from the Southern Country is the gold standard."

"What’s more, we can conduct follow-ups and spend a little money on a PR campaign. We’ll highlight the vast majority of patients who have good tolerance and compliance, while burying the cases with adverse reactions."

"After the final recall, we can even selectively pick a representative case—a patient who suffered an adverse reaction—and offer them an exorbitant compensation package."

"Imagine the narrative: a new drug, praised within patient communities for its remarkable efficacy, gets recalled over a handful of adverse reactions. The company even pays out a massive settlement. It would be a legend—a miracle drug that flashed across the sky like a meteor."

"For Pfizer, this will actually only bolster our reputation and public image."

"Remember, this is Jin Country. The general public here instinctively reveres Pfizer and the standards set by the FDA."

Xie Bin continued to tempt him:

"So, from start to finish, this entire affair is virtually risk-free. And our reward? We get to destroy a rising local pharmaceutical company in Jin Country, one that prides itself on independent R&D. We acquire all its valuable assets. And from all this, we stand to make a profit in the tens of billions."

"President Xu, I don’t understand. What are you hesitating about?"

Faced with enormous profit and minimal risk, Xu Kunlin chose to go along with the scheme.

"But what about the patients who suffer severe adverse reactions, or even die...?"

Xu Kunlin still felt a pang of conscience.

"What drug doesn’t have fatalities? Every medicine is a potential poison. Besides, they’re already late-stage liver cancer patients. Maybe this is the best way out for them."

Xie Bin couldn’t care less if these patients lived or died.

Xu Kunlin’s hesitation vanished completely.

"Use Lou Musaang’s connections and Wu Ting’s team’s project as our entry point. Find a suitable opportunity to go and ’inspect’ Jin Pharmaceutical Group. While you’re there, make an offer to acquire their Yangzheng Xiujie Pill project... Of course, we’re not actually trying to buy it. We just want to give them the impression that we’re very interested in the project and see its value."

"Make the offer a high one. When they refuse, act a little offended..."

Xie Bin straightened Xu Kunlin’s suit and continued to instruct:

"After you get back, hold a press conference at our Pfizer Jin Country Research Center in Xianglin City. Announce that we’re launching a project to compete with the Yangzheng Xiujie Pill. Make a splash by announcing an astonishing two billion in initial funding. That should give Jin Pharmaceutical Group some pressure... and motivation."

"At the same time, start spreading rumors that are favorable to the Yangzheng Xiujie Pill project. We want to constantly drive up Jin Pharmaceutical Group’s stock price..."

"In the meantime, I’ll head back to the Southern Country and push through the FDA certification for Sorafenib. After that, all we have to do is wait for Jin Pharmaceutical Group to hold the launch event for their new drug... and then we’ll hit them head-on!"

With the plan laid out, Xie Bin began contacting his various connections. He calculated every strategic step with precision, ensuring all necessary support from various parties was firmly in place.

...

...

Wu Ting and Deng Feifei had been inseparable during this time, their relationship advancing by leaps and bounds.

Over this period, Wu Ting had managed to dig up a great deal of information about Jin Pharmaceutical Group’s research and development center.

Two people in particular, two absolute powerhouses, had Wu Ting practically drooling.

One was the person in charge of the project codenamed "Banzhe," who was also the chief scientist of Jin Pharmaceutical Group’s R&D center, Lou Musaang.

The second was Dr. Jia Jun, the person in charge of the new drug project "Yangzheng Xiujie Pill," which had already entered Phase III clinical trials.

Wu Ting learned from Deng Feifei that both men were top-tier domestic geniuses in the R&D of traditional Chinese patent medicines. Furthermore, they both possessed extensive experience and a unique talent for developing original oncology drugs.

Unfortunately, these two were core assets of Jin Pharmaceutical Group, as well as its top scientists.